This site is intended for Healthcare professionals only.

Zydus Cadila gets USFDA nod for Exemestane Tablet


Zydus Cadila gets USFDA nod for Exemestane Tablet

New Delhi: Drug firm Zydus Cadila has received final approval from the US health regulator to market Exemestane tablets, used for the treatment of breast cancer. The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 25 mg, Zydus Cadila said in a BSE filing.

The company said it will manufacture the drug at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Quoting IMS Health data for August 2018, the company said the estimated sale for Exemestane tablets is USD 68.6 million.

Zydus Cadila has more than 220 approvals and so far filed over 330 abbreviated new drug applications (ANDAs).

Read Also: Zydus Cadila gets USFDA nod for Desoximetasone cream



Source: PTI
0 comment(s) on Zydus Cadila gets USFDA nod for Exemestane Tablet

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted